Darshil Ingle*
Achal Jane
The selection of a drug administration route is fundamental to a therapeutic regimen's efficacy, safety, and patient compliance¹. While the oral route is convenient, it frequently results in poor bioavailability for numerous drugs, primarily due to degradation in the gastrointestinal tract and the inevitable hepatic first-pass effect². Conversely, parenteral routes (injections) offer high systemic bioavailability but are fraught with disadvantages, including associated pain, risk of infection, phobia (trypanophobia), and the consistent need for trained medical personnel3,4. Transdermal Drug Delivery Systems (TDDS) were developed as a non-invasive, patient-friendly alternative, providing controlled and sustained drug release directly into the systemic circulation, thus avoiding first-pass metabolism and maintaining stable plasma concentrations However, the major hurdle for TDDS is the stratum corneum (SC), the outermost layer of the epidermis typically 10–20 µm thick (ranging up to 40 µm in some body sites), which functions as the primary permeability barrier 5,6This dense, lipid-rich barrier effectively limits the transdermal permeation of most therapeutic agents, particularly those with a molecular weight greater than 500 Da, hydrophilic nature, or ionic charge7. The SC consists of corneocytes embedded in a lipid matrix organized in a highly ordered lamellar structure, creating a tortuous pathway that restricts molecular diffusion⁸. To overcome the SC barrier, researchers have developed various physical enhancement techniques, such as iontophoresis, electroporation, sonophoresis, and thermophoresis 9 Among these, Microneedle (MN) technology has emerged as the most promising platform, representing a true "third-generation" transdermal delivery approach that physically and minimally bypasses the SC 10MN arrays consist of micron-scale projections, typically ranging from 150 to 1500 µm in length, which are long enough to penetrate the non-vascularized epidermis but intentionally too short to reach the underlying pain receptors and capillaries in the dermis¹¹. This design enables painless, minimally invasive delivery, facilitating the systemic absorption of both small-molecule drugs and high-molecular-weight biologics¹². The evolution of MN technology can be traced back to the late 1990s when the first silicon-based microneedle arrays were fabricated using microelectromechanical systems (MEMS) technology¹³. Since then, the field has witnessed exponential growth, with over 1,000 research publications and numerous patents filed annually¹⁴. The technology has progressed from proof-of-concept studies to clinical trials and, in some cases, commercial products15,16
Materials and Methods (Classification, Materials, and Fabrication)
As a comprehensive review, this section details the physical anatomy of microneedle action, the classification by structure and mechanism, the diverse materials utilized, and the sophisticated fabrication techniques employed.
Anatomy and Mechanism of Action
Microneedles exploit the skin's structural anatomy to create transient permeability pathways. The skin comprises three primary layers: the epidermis (50–150 µm thick), dermis (1–3 mm thick), and subcutaneous tissue¹⁷. The MNs are sized to pierce the SC and the viable epidermis, typically stopping above the dermal layer². The key parameters of MN design—length, tip radius, base width, aspect ratio, and array density—are optimized to maximize penetration efficacy while minimizing dermal stimulation¹⁸. Upon application, the MNs create microchannels that serve as temporary aqueous shunts, allowing the drug to bypass the lipid-rich SC barrier and move directly into the dermal microcirculation 19The insertion depth depends on multiple factors including needle geometry, applied force, skin properties (age, hydration, anatomical site), and application technique²⁰. These micro-lesions are self-closing, often healing within minutes to hours through the natural wound-healing process, which ensures skin barrier restoration and minimizes the risk of infection²¹. The permeability enhancement created by MNs is quantified by the permeability coefficient and can increase drug flux by several orders of magnitude compared to intact skin²². Studies have demonstrated that MN-created microchannels remain patent for 2–48 hours depending on the needle geometry and skin properties, providing sufficient time for drug permeation²³.
Classification and Delivery Mechanisms
Microneedles are classified based on their structure, material composition, and the corresponding drug delivery mechanism, each tailored for a specific therapeutic need²⁴.
Table 1: Classification of Microneedle Types and Delivery Mechanisms.
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Solid MNs |
Applied topically after puncture |
Passive diffusion through microchannels. |
|
2 |
Coated MNs |
Drug in a thin layer on needle surface |
Rapid dissolution of the coating layer in interstitial fluid. |
|
3 |
Dissolving MNs |
Drug encapsulated within needle matrix |
Degradation/dissolution of the entire polymer matrix. |
|
4 |
Hollow MNs |
Liquid drug solution in a reservoir |
Pressure-driven flow (infusion/perfusion) through the bore. |
|
5 |
Hydrogel MNs |
Drug in a cross-linked polymer matrix |
Swelling upon hydration, followed by drug diffusion out of the hydrogel. |
Each MN type offers distinct advantages: solid MNs provide robust mechanical properties; coated MNs enable rapid vaccine delivery; dissolving MNs eliminate sharps waste and offer controlled release; hollow MNs allow for high-dose liquid formulations; and hydrogel MNs provide extended release kinetics25,26
Materials Used in MN Fabrication
The selection of the fabrication material is paramount, dictating the needle's mechanical strength, stability, biocompatibility, and biofate (non-degradable vs. degradable) ²⁷.
Table 2: Key Materials for Microneedle Fabrication
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Non-Degradable Metal |
Stainless Steel, Titanium, Nickel |
Superior mechanical strength, High fracture toughness, Excellent reproducibility. |
|
2 |
Non-Degradable Silicon |
Crystalline Silicon |
High precision, Etching capability for sharp tips, Well-established fabrication protocols. |
|
3 |
Water-Soluble Polymers |
Hyaluronic acid (HA), PVP, PVA, Dextrin, CMC |
Excellent biocompatibility, Tunable dissolution rate, No sharp waste, FDA-approved excipients. |
|
4 |
Biodegradable Polymers |
PLGA, Polylactic Acid (PLA), PCL |
Controlled degradation rate, FDA-approved (PLGA), Programmable release kinetics. |
|
5 |
Carbohydrates |
Maltose, Sucrose, Trehalose, Glucose |
Very high-water solubility, Fast dissolution rate, GRAS status, Protein stabilization. |
|
6 |
Ceramic Materials |
Calcium sulfate, Hydroxyapatite |
High mechanical strength, Biocompatible, Osseoconductive properties. |
Recent developments have explored composite materials that combine the mechanical strength of one material with the biocompatibility of another²⁸. For instance, metal-polymer composites and ceramic-polymer hybrids have shown promise in achieving optimal mechanical and biological properties²⁹.
Fabrication Techniques
Fabrication aims for high-precision control over needle geometry and array density, with a focus on cost-effective, high-throughput scalability³⁰.
Table 3: Overview of Microneedle Fabrication Techniques
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Micro-Molding/Casting |
Polymers (Dissolving, Hydrogel) |
Pouring liquid polymer/drug solution into a master mold, followed by curing/drying. |
|
2 |
Lithography/ Etching |
Silicon, Metal (Master Molds) |
Utilizes photolithography and Deep Reactive Ion Etching (DRIE) from the semiconductor industry. |
|
3 |
Laser-Based Techniques |
Metal, Solid Polymers |
Laser cutting or ablation to define needle structures using focused laser beams. |
|
4 |
3D Printing (Additive) |
Polymers, Composites, Ceramics |
Layer-by-layer construction (e.g., micro-stereolithography, two-photon polymerization). |
|
5 |
Dip-Coating |
Solid MNs (Metal, Silicon) |
Dipping a solid array into a drug/polymer solution; solvent evaporates leaving a drug layer. |
|
6 |
Drawing Lithography |
Glass, Polymers |
Vertical pulling of softened material to create needle-like structures. |
|
7 |
Injection Molding |
Thermoplastics |
High-pressure injection of molten polymer into precision molds. |
Emerging fabrication techniques include roll-to-roll manufacturing for continuous production³¹, electrospinning for creating nanostructured MNs³², and self-assembly methods for bottom-up fabrication³³. Quality control parameters such as needle height uniformity, tip sharpness, mechanical strength, and sterility are critical for regulatory approval³⁴.
RESULTS
This section details the diverse therapeutic, diagnostic, and cosmetic applications of MN technology.
Applications of Microneedle Technology
MN technology's versatility supports a broad range of applications across healthcare³⁵.
A. Pharmaceutical and Clinical Applications
Vaccine Delivery: The dermis is rich in Antigen-Presenting Cells (APCs), notably Langerhans cells and dermal dendritic cells, making it an ideal target for immunization³⁶. MN patches (mostly coated or dissolving) deliver vaccines directly to these immune cells, often requiring a lower dose (up to 90% dose reduction) than intramuscular injection due to enhanced immunogenicity³⁷. Crucially, the formulation in a solid-state patch offers thermostability, eliminating the costly and complex "cold chain" required for liquid vaccines, thus simplifying logistics for global immunization efforts³⁸. Clinical trials have demonstrated the efficacy of MN-delivered vaccines for multiple diseases. A landmark phase 1/2 trial in The Gambia showed that a measles and rubella vaccine delivered via microneedle patch was safe, well-tolerated, and immunogenic in children³⁹. Similarly, influenza vaccine MN patches have completed multiple clinical trials with promising results⁴⁰. COVID-19 vaccine MN platforms have been extensively researched, with several formulations showing stability at room temperature for over 12 months⁴¹. Other vaccines under development include those for polio, hepatitis B, HPV, and tuberculosis (BCG)42,43
Delivery of Biologics and Peptides: The platform is a breakthrough for systemically delivering high molecular weight drugs (macromolecules) that are degraded orally, such as insulin, growth hormones, monoclonal antibodies, and gene therapies⁴⁴. Glucose-responsive MNs, which release insulin only when blood glucose levels are elevated, are a key area of research for closed-loop diabetes management⁴⁵. These "smart" MNs incorporate glucose-oxidase or phenylboronic acid moieties that respond to hyperglycemic conditions⁴⁶. Other biologics successfully delivered via MNs include: parathyroid hormone for osteoporosis⁴⁷, erythropoietin for anemia⁴⁸, interferons for hepatitis⁴⁹, and various monoclonal antibodies for cancer immunotherapy⁵⁰. The MN route offers improved pharmacokinetics compared to subcutaneous injection, with faster onset and more predictable absorption profiles⁵¹.
Localized Treatment: MNs ensure high local drug concentrations with minimal systemic exposure for targeted therapies⁵². This is effective in dermatology for conditions like psoriasis (methotrexate delivery), skin cancers (transdermal chemotherapy with 5-fluorouracil or paclitaxel), alopecia (minoxidil delivery), and acne (tretinoin delivery), delivering potent drugs directly to the lesion site⁵³. MN-mediated photodynamic therapy has shown enhanced outcomes for basal cell carcinoma⁵⁴.
Diagnostics and Monitoring: Hollow MNs or surface-modified MNs can penetrate the SC to sample interstitial fluid (ISF), a biological fluid rich in biomarkers (e.g., glucose, lactate, K⁺, urea, proteins, antibodies), for continuous or on-demand monitoring⁵⁵. The integration of MNs with electrochemical sensors creates wearable biosensors for real-time health monitoring⁵⁶. Recent advances include MN-based continuous glucose monitors that rival commercial subcutaneous sensors in accuracy⁵⁷, multiplexed biomarker detection for diabetes management⁵⁸, and therapeutic drug monitoring systems⁵⁹.
Table 4: Comparison of Various Drug Delivery System
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Oral |
Low/Variable |
Excellent |
|
2 |
Parenteral (Injection) |
High (near 100%) |
Low (due to pain/phobia) |
|
3 |
Conventional TDDS |
Low |
Good |
|
4 |
Microneedle (MN) |
High/Tunable |
Excellent |
B. Cosmeceutical and Aesthetic Applications
MNs are used to enhance the penetration of high molecular weight cosmetic agents (e.g., hyaluronic acid, collagen, vitamins C and E, peptides, growth factors) that normally cannot cross the SC⁶⁰. Furthermore, the micro-injuries created by MNs in the dermis trigger a wound-healing cascade, stimulating the production of new collagen and elastin through increased expression of growth factors like TGF-β and VEGF, a process known as Percutaneous Collagen Induction Therapy (Microneedling), used for scar revision, wrinkle reduction, hyperpigmentation treatment, and anti-aging⁶¹. Clinical studies have demonstrated significant improvements in facial skin texture, pore size, and elasticity following MN treatments⁶². The combination of MN with radiofrequency energy (RF-MN) has shown enhanced efficacy for skin tightening and rejuvenation⁶³. MN-mediated delivery of stem cell-derived exosomes and growth factors represents a frontier in regenerative aesthetics⁶⁴.
DISCUSSION
Despite remarkable progress, the clinical and commercial translation of MN technology faces significant hurdles. This section discusses the critical technological and regulatory challenges hindering widespread clinical adoption and explores the future trajectory of the field.
Challenges and Future Trajectory
Table 5: Key Challenge and Proposed Solution for Micro needle Drug Delivery
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Mechanical Integrity |
Buckling or fracture of needles (especially polymer/sugar MNs) upon insertion force. |
Risk of needle residue in the skin, reduced efficacy, safety concern. |
|
2 |
Dose Limitation |
Small surface area of Coated MNs limits the maximum drug load (typically few mg). |
Not suitable for drugs requiring high systemic doses. |
|
3 |
Manufacturing Cost |
High capital investment for precision techniques (Lithography, 3D printing). |
Increased final product cost, slowing market adoption. |
|
4 |
Stability & Shelf Life |
Fragility of drug-loaded MN patches; stability of biologics in the solid state. |
Requires specialized packaging, limits global distribution, cold chain dependency for some formulations. |
|
5 |
Regulatory Standard |
Lack of standardized testing protocols for penetration force, dose accuracy and biocompatibility. |
Slows down FDA/EMA approval and clinical translation. |
|
6 |
Skin Variability |
Differences in skin thickness, hydration, age affect penetration efficiency. |
Inconsistent drug delivery across patient populations. |
|
7 |
Infection Risk |
Although minimal, risk of microbial contamination through microchannels. |
Safety concerns, especially for immunocompromised patients. |
The regulatory pathway for MN products remains complex, as they represent a combination drug-device product requiring evaluation under both pharmaceutical and medical device frameworks⁶⁵. The FDA and EMA have issued draft guidance documents, but definitive standards are still evolving⁶⁶.
Future Directions and Opportunities
The future of MN technology is focused on integration, intelligence, and accessibility.
Table 6: Emerging Trends and Opportunities
|
Sr. No. |
Column 1 |
Column 2 |
Column 3 |
|
1 |
Stimuli-Responsive MNs |
MNs made of materials that sense and respond to biological triggers (e.g., pH, temperature, glucose, enzymes, reactive oxygen species). |
Closed-loop drug delivery (e.g., auto-insulin release), highly targeted therapy for inflammatory sites, cancer microenvironment-responsive chemotherapy. |
|
2 |
Integrated Wearable MNs |
Combining MN biosensors with microelectronics, wireless communication modules, and power sources. |
Continuous, painless, real-time health monitoring (e.g., glucose, drug metabolites, cortisol, electrolytes) in a comfortable patch, IoMT integration. |
|
3 |
Trans-Mucosal Delivery |
Applying MNs to non-skin barriers like ocular, buccal (mouth), vaginal, or nasal mucosa. |
Localized treatment of mucosal diseases, systemic delivery bypassing the harsh digestive environment, enhanced vaccine absorption. |
|
4 |
Combination Therapy MNs |
Single MN patch delivering multiple drugs or combining MN action with other enhancement methods (e.g., iontophoresis, sonophoresis). |
Synergistic treatment for complex diseases like cancer or chronic wounds, reduced treatment burden, improved adherence. |
|
5 |
Personalized Fabrication |
Utilizing high-speed 3D printing (Additive Manufacturing) to customize dose, geometry, and drug combinations. |
MN patch tailored to a patient's specific skin properties, disease state, and dosage requirements, precision medicine applications. |
|
6 |
Nanoparticle-Loaded MNs |
Integration of nanoparticles (liposomes, polymeric NPs, inorganic NPs) within MN matrix for controlled release. |
Prolonged drug action, targeted delivery to specific cells, combination of imaging and therapy (theranostics), enhanced protein stability. |
|
7 |
Artificial Intelligence Integration |
AI-driven optimization of MN design, manufacturing, and patient-specific dosing algorithms. |
Accelerated development cycles, predictive modeling of drug release, personalized treatment algorithms, quality control automation. |
Emerging applications include MN-based delivery of gene editing tools (CRISPR-Cas9) ⁶⁷, cell-based therapies⁶⁸, and probiotics for skin microbiome modulation⁶⁹. The integration of MN technology with organ-on-chip platforms for drug testing represents another frontier⁷⁰.
CONCLUSION
Microneedle (MN) technology stands as a powerful, transformative platform for drug delivery, diagnostics, and cosmetology, primarily due to its ability to painlessly and minimally invasively breach the stratum corneum barrier⁷¹. It successfully addresses several major limitations of conventional administration methods by enabling the efficient transdermal delivery of macromolecules (proteins, peptides, vaccines), significantly improving patient compliance by eliminating needle phobia, and allowing for controlled and sustained drug release profiles⁷². While challenges related to manufacturing scalability, mechanical reliability, dose limitations, and the need for standardized regulatory pathways still exist, the field is rapidly maturing⁷³. The convergence of advanced materials science, microfabrication techniques, and digital health technologies is accelerating the translation of MN platforms from laboratory to clinic⁷⁴. The future trajectory involves the commercial launch of highly stable MN-based vaccine and therapeutic products, alongside the widespread development of smart, integrated MNs for continuous monitoring and personalized, closed-loop treatment⁷⁵. Several MN products have already received regulatory approval or are in late-stage clinical trials, signaling the imminent mainstreaming of this technology⁷⁶. Microneedle technology is decisively poised to become a preferred, patient-centric route of administration, revolutionizing drug delivery and diagnosis across the global healthcare sector⁷⁷. As the technology continues to evolve, it holds particular promise for addressing global health challenges in resource-limited settings, where the elimination of cold chain requirements and the potential for self-administration can dramatically improve access to saving vaccines and therapeutics78.
REFERENCE
- Rani, M. S. and P. V. Babu, Microneedles: A Novel Approach in Transdermal Drug Delivery: Review Paper, International Journal of Pharmaceutical and Bio Medical Science, 3(11), 2023, 652–661.
- Wang, J., Y. Ye, and R. Li, Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review, ACS Materials Au, 2023.
- Guillot, A. J., A. S. Cordeiro, R. F. Donnelly, M. C. Montesinos, T. M. Garrigues, and A. Melero, Microneedle-Based Delivery: An Overview of Current Applications and Trends, Pharmaceutics, 12(6), 2020, 569.
- Bhati, A., R. Sharma, and M. Dube, View of Microneedles in Transdermal Drug Delivery: A Comprehensive Review, Journal of Drug Delivery and Therapeutics, 14(3), 2024, 173–182.
- Chen, M., G. Quan, Y. Sun, D. Yang, X. Pan, and C. Wu, Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery, Journal of Controlled Release, 325, 2020, 163–175.
- Lin, Z., et al., Exploring the Chronology and Typology of Microneedles: Insights from History and Classification, Labinsights, 2023.
- Zhu, Q., D. Feng, R. Li, and M. Wu, Microneedle System for Transdermal Drug and Vaccine Delivery: Devices, Safety, and Prospects, Drug Delivery and Translational Research, 10, 2019, 1–18.
- Lee, H. J. and H. K. Choi, Microneedles in Action: Microneedling and Microneedles-Assisted Transdermal Delivery, Polymers, 14(8), 2022, 1608.
- Jaiswal, S., et al., Microneedling in Dermatology: A Comprehensive Review of Applications, Techniques, and Outcomes, Cureus, 16(10), 2024.
- Ghasemiyeh, Z. and R. Dinarvand, An overview of microneedle applications, materials, and fabrication methods, Beilstein Journal of Nanotechnology, 12, 2021, 1007–1026.
- Lee, K., et al., Microneedle for transdermal drug delivery: current trends and fabrication, Biomaterials Research, 25(1), 2021, 1–18.
- Alkilani, A. Z., et al., Recent Advances in Microneedle Platforms for Transdermal Drug Delivery Technologies, Polymers, 15(15), 2023, 3224.
- Nagarkar, R., et al., Mechanism of drug delivery by microneedle device, ResearchGate, 2024.
- Chandrashekar, K. K., et al., Microneedles in Drug Delivery: Progress and Challenges, Pharmaceutics, 13(11), 2021, 1968.
- Dhasmana, A., et al., Microneedle-based drug delivery: materials of construction, Journal of Chemical Sciences, 133(1), 2021, 10.
- Prausnitz, M. R., Engineering microneedle patches for vaccination and drug delivery to skin, Annual Review of Chemical and Biomolecular Engineering, 8, 2017, 177–200.
- Dharadhar, S., A. Majumdar, S. Dhoble, and V. Patravale, Microneedles for transdermal drug delivery: a systematic review, Drug Development and Industrial Pharmacy, 45(2), 2019, 188–201.
- Haq, M. I., E. Smith, D. N. John, M. Kalavala, C. Edwards, A. Anstey, A. Morrissey, and J. C. Birchall, Clinical administration of microneedles: skin puncture, pain and sensation, Biomedical Microdevices, 11(1), 2009, 35–47.
- Kim, Y. C., J. H. Park, and M. R. Prausnitz, Microneedles for drug and vaccine delivery, Advanced Drug Delivery Reviews, 64(14), 2012, 1547–1568.
- Donnelly, R. F., T. R. Singh, and A. D. Woolfson, Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety, Drug Delivery, 17(4), 2010, 187–207.
- Gupta, J., E. I. Felner, and M. R. Prausnitz, minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles, Diabetes Technology & Therapeutics, 11(6), 2009, 329–337.
- Gill, H. S. and M. R. Prausnitz, Coated microneedles for transdermal delivery, Journal of Controlled Release, 117(2), 2007, 227–237.
- Kalluri, H. and A. K. Banga, Formation and closure of microchannels in skin following microporation, Pharmaceutical Research, 28(1), 2011, 82–94.
- van der Maaden, K., W. Jiskoot, and J. Bouwstra, Microneedle technologies for transdermal drug and vaccine delivery, Journal of Controlled Release, 161(2), 2012, 645–655.
- Rodgers, A. M., A. S. Cordeiro, and R. F. Donnelly, Technology update: dissolvable microneedle patches for vaccine delivery, Medical Devices: Evidence and Research, 12, 2019, 379–398.
- Chen, B. Z., L. Q. Zhang, Y. Y. Xia, X. P. Zhang, and X. D. Guo, A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control, Science Advances, 7(21), 2021
- Lutton, R. E., E. Larrañeta, M. C. Kearney, P. Boyd, A. D. Woolfson, and R. F. Donnelly, A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays, International Journal of Pharmaceutics, 494(1), 2015, 417–429.
- Yang, S., F. Wu, J. Liu, G. Fan, W. Welsh, H. Zhu, and T. Jin, Phase-transition microneedle patches for efficient and accurate transdermal delivery of insulin, Advanced Functional Materials, 25(29), 2015, 4633–4641.
- Du, H., P. Liu, J. Zhu, J. Lan, Y. Li, L. Zhang, J. Zhu, and J. Tao, Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis, ACS Applied Materials & Interfaces, 11(46), 2019, 43588–43598.
- Park, J. H., M. G. Allen, and M. R. Prausnitz, Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery, Journal of Controlled Release, 104(1), 2005, 51–66.
- Economidou, S. N., C. P. P. Pere, A. Reid, M. J. Uddin, J. F. Windmill, D. A. Lamprou, and D. Douroumis, 3D printed microneedle patches using stereolithography (SLA) for intradermal insulin delivery, Materials Science and Engineering: C, 102, 2019, 743–755.
- Sartawi, Z., C. Blackshields, and H. M. Fadda, Dissolving microneedles: applications and growing therapeutic potential, Journal of Controlled Release, 348, 2022, 186–205.
- Lee, J. W., J. H. Park, and M. R. Prausnitz, Dissolving microneedles for transdermal drug delivery, Biomaterials, 29(13), 2008, 2113–2124.
- Larraneta, E., R. E. Lutton, A. D. Woolfson, and R. F. Donnelly, Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development, Materials Science and Engineering: R: Reports, 104, 2016, 1–32.
- Waghule, T., G. Singhvi, S. K. Dubey, M. M. Pandey, G. Gupta, M. Singh, and K. Dua, Microneedles: a smart approach and increasing potential for transdermal drug delivery system, Biomedicine & Pharmacotherapy, 109, 2019, 1249–1258.
- Combadière, B. and C. Liard, Transcutaneous and intradermal vaccination, Human Vaccines, 7(8), 2011, 811–827.
- Kis, E. E., G. Winter, and J. Myschik, Devices for intradermal vaccination, Vaccine, 30(3), 2012, 523–538.
- Mistilis, M. J., J. C. Joyce, E. S. Esser, I. Skountzou, R. W. Compans, A. S. Bommarius, and M. R. Prausnitz, Long-term stability of influenza vaccine in a dissolving microneedle patch, Drug Delivery and Translational Research, 7(2), 2017, 195–205.
- Bakker, M., L. de Waal, W. van Rijs, N. Donders, P. Traverse, S. Slamanig, R. Kompier, A. van Rie, and G. Kersten, First-in-human trial of a microarray patch (MAP) for immunization against influenza: a randomized, controlled phase 1 trial, Vaccine, 40(5), 2022, 787–794.
- Fernando, G. J., X. Chen, T. W. Prow, M. L. Crichton, E. J. Fairmaid, M. S. Roberts, I. H. Frazer, L. E. Brown, and M. A. Kendall, Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model, PLoS ONE, 5(4), 2010, e10266.
- Edens, C., M. L. Collins, J. Ayers, P. A. Rota, and M. R. Prausnitz, Measles vaccination using a microneedle patch, Vaccine, 33(37), 2015, 4712–4718.
- Joyce, J. C., T. D. Carroll, M. L. Collins, M. H. Chen, L. Fritts, J. C. Dutra, Y. M. Roshorm, T. K. Resch, M. A. Murphey-Corb, and C. R. King, A microneedle patch for measles and rubella vaccination is immunogenic in infant rhesus macaques, *Journal of Infectious Diseases, 216(10), 2017, 1344–1353.
- Sharma, S., K. Hatware, P. Bhadane, S. Sindhikar, and D. K. Mishra, Recent advances in microneedle composites for biomedical applications: Advanced drug delivery technologies, Materials Science and Engineering: C, 103, 2019, 109717.
- Arya, J., S. Henry, H. Kalluri, D. V. McAllister, W. P. Pewin, and M. R. Prausnitz, Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects, Biomaterials,128, 2017, 1–7.
- Yu, J., Y. Zhang, Y. Ye, R. DiSanto, W. Sun, D. Ranson, F. S. Ligler, J. B. Buse, and Z. Gu, Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery, Proceedings of the National Academy of Sciences, 112(27), 2015, 8260–8265.
- Wang, J., Y. Ye, J. Yu, A. R. Kahkoska, X. Zhang, C. Wang, W. Sun, R. D. Corder, Z. Chen, S. A. Khan, J. B. Buse, and Z. Gu, Core–shell microneedle gel for self-regulated insulin delivery, ACS Nano, 10(12), 2016, 11505–11513.
- Caffarel-Salvador, E., A. J. Brady, E. Eltayib, T. Meng, A. Alonso-Vicente, P. Gonzalez-Vazquez, B. M. Torrisi, E. M. Vicente-Perez, K. Mooney, D. S. Jones, S. E. Bell, C. P. McCoy, H. O. McCarthy, J. C. McElnay, and R. F. Donnelly, Hydrogel-forming microneedle arrays allow detection of drugs and glucose in vivo: potential for use in diagnosis and therapeutic drug monitoring, PLoS ONE, 10(12), 2015, e0145644.
- Chen, M. C., Z. W. Lin, and M. H. Ling, Near-infrared light-activatable microneedle system for treating superficial tumors by combination of chemotherapy and photothermal therapy, ACS Nano, 10(1), 2016, 93–101.
- Ita, K., Transdermal delivery of drugs with microneedles—potential and challenges, Pharmaceutics, 7(3), 2015, 90–105.
- Chen, S., H. Matsumoto, Y. Moro-oka, M. Tanaka, Y. Miyahara, T. Suganami, and A. Matsumoto, Microneedle-array patch fabricated with enzyme-free polymeric components capable of on-demand insulin delivery, Advanced Functional Materials, 29(5), 2019, 1807369.
- Lee, K. and H. Jung, Drawing lithography for microneedles: a review of fundamentals and biomedical applications, Biomaterials,33(30), 2012, 7309–7326.
- Bhatnagar, S., K. Dave, and V. V. Venuganti, Microneedles in the clinic, Journal of Controlled Release, 260, 2017, 164–182.
- Chen, Y., B. Z. Chen, Q. L. Wang, X. Jin, and X. D. Guo, Fabrication of coated polymer microneedles for transdermal drug delivery, Journal of Controlled Release, 265, 2017, 14–21.
- Brogden, N. K., M. Milewski, P. Ghosh, L. Hardi, L. J. Crofford, and A. L. Stinchcomb, Diclofenac delays micropore closure following microneedle treatment in human subjects, Journal of Controlled Release,163(2), 2012, 220–229.
- Mohan, A. V., J. R. Windmiller, R. K. Mishra, and J. Wang, Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays, Biosensors and Bioelectronics, 91, 2017, 574–579.
- Mukerjee, E. V., S. D. Collins, R. R. Isseroff, and R. L. Smith, Microneedle array for transdermal biological fluid extraction and in situ analysis, Sensors and Actuators A: Physical, 114(2-3), 2004, 267–275.
- Chinnadayyala, S. R., I. Park, and S. Cho, Nonenzymatic determination of glucose at near neutral pH values based on the use of nafion and platinum black coated microneedle electrode array, Microchimica Acta, 185(5), 2018, 250.
- Ribet, F., G. Stemme, and N. Roxhed, Real-time intradermal continuous glucose monitoring using a minimally invasive microneedle-based system, Biomedical Microdevices, 19(4), 2017, 101.
- Samant, P. P. and M. R. Prausnitz, Mechanisms of sampling interstitial fluid from skin using a microneedle patch, Proceedings of the National Academy of Sciences,115(18), 2018, 4583–4588.
- Fang, J. Y., W. R. Lee, S. C. Shen, Y. P. Fang, and C. H. Hu, Enhancement of topical 5-aminolaevulinic acid delivery by erbium:YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation, British Journal of Dermatology, 151(1), 2004, 132–140.
- Osman, M., K. Khalid, Z. Mohamad, N. Ismail, and N. Ahmad, Microneedling therapy for atrophic acne scars: A systematic review and meta-analysis, Journal of Cosmetic Dermatology, 21(3), 2022, 929–938.
- Alster, T. S. and P. M. Graham, Microneedling: A review and practical guide, Dermatologic Surgery, 44(3), 2018, 397–404.
- Aust, M. C., D. Fernandes, P. Kolokythas, H. M. Kaplan, and P. M. Vogt, Percutaneous collagen induction therapy: an alternative treatment for scars, wrinkles, and skin laxity, Plastic and Reconstructive Surgery,121(4), 2008, 1421–1429.
- Doddaballapur, S., Microneedling with dermaroller, Journal of Cutaneous and Aesthetic Surgery, 2(2), 2009, 110–111.
- Ameri, M., P. E. Daddona, and Y. F. Maa, Demonstrated solid-state stability of parathyroid hormone PTH (1-34) coated on a novel transdermal microprojection delivery system, Pharmaceutical Research, 26(11), 2009, 2454–2463.
- European Medicines Agency, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2018, 2020.
- Luo, X., L. Yang, Y. Cui, L. Pang, Z. Li, Z. Song, Y. Zhang, and Y. Cui, Preparation and drug release property of triptolide-loaded solid dispersion in poly (vinyl pyrrolidone) matrix by hot-melt extrusion, AAPS PharmSciTech, 22(1), 2021, 29.
- Liu, T., M. Chen, J. Fu, Y. Sun, C. Lu, G. Quan, X. Pan, and C. Wu, Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs, Acta Pharmaceutica Sinica B, 11(8), 2021, 2326–2343.
- Nayak, A., D. B. Das, and G. T. Vladisavljević, Microneedle-assisted permeation of lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel, Pharmaceutics, 12(3), 2020, 291.
- Kapoor, Y., M. Milewski, L. Dick, J. Zhang, J. R. Bothe, M. Gehrt, K. Manser, B. Nissley, I. Petrescu, P. Johnson, and C. H. Borca, Coated microneedles for transdermal delivery of a potent pharmaceutical peptide, Biomedical Microdevices, 22(3), 2020, 44.
- Nguyen, H. X. and A. K. Banga, Delivery of therapeutic agents via transdermal route: an introduction, In Transdermal and Intradermal Delivery of Therapeutic Agents, 2018, 1-10.
- Sullivan, S. P., N. Murthy, and M. R. Prausnitz, Minimally invasive protein delivery with rapidly dissolving polymer microneedles, Advanced Materials, 20(5), 2008, 933–938.
- Mönkäre, J., M. Pontier, E. E. van Kampen, G. Du, M. Leone, S. Romeijn, M. R. Nejadnik, C. O’Mahony, B. Slütter, W. Jiskoot, and J. A. Bouwstra, Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery, European Journal of Pharmaceutics and Biopharmaceutics, 129, 2018, 111–121.
- Cole, G., A. A. Ali, E. McErlean, E. J. Mulholland, A. Short, C. M. McCrudden, J. McCaffrey, T. Robson, V. L. Kett, J. A. Coulter, R. F. Donnelly, and H. O. McCarthy, DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen, Acta Biomaterialia,96, 2019, 480–490.
- Ingrole, R. S., H. S. Gill, and M. R. Prausnitz, Microneedle coating methods: A review with a perspective, Journal of Pharmacology and Experimental Therapeutics, 370(3), 2019, 555–569.
- Caudill, C. L., J. L. Perry, K. Iliadis, A. T. Tessema, B. J. Lee, B. S. Mecham, S. Tian, and J. M. DeSimone, Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity, Proceedings of the National Academy of Sciences, 118(39), 2021, e2102595118.
- Sabri, A. H., J. Ogilvie, K. Abdulhamid, V. Shpadaruk, J. McKenna, J. Segal, D. J. Scurr, and M. Marlow, Expanding the applications of microneedles in dermatology, European Journal of Pharmaceutics and Biopharmaceutics, 154, 2020, 111–122.
- Prausnitz, M. R. and R. Langer, Transdermal drug delivery, Nature Biotechnology, 26(11), 2008, 1261–1268.
10.5281/zenodo.19543352